Picture ConsulTech GmbH Berlin Grant Application and Coordination 650x80px
Document › Details

Thuja Capital Management. (12/21/21). "Press Release: Thuja Announces the Final Close of Thuja Capital Healthcare Fund III at EUR 76M (USD 86M)". Utrecht.

Region Region Belgium
Organisations Organisation Thuja Capital Healthcare Fund III
  Group Thuja Capital (Group)
  Organisation 2 European Investment Fund (EIF)
  Group EU (govt)
Product Product  pharmaceutical
Index term Index term Thuja Capital–SEVERAL: investment, 202112 final closing of Thuja Capital Heathcare Fund III at €76m incl investor EIF

Thuja Capital Management, an early stage life sciences investor, today announces the final close of its Thuja Capital Healthcare Fund III ("Fund III") at EUR 76M. Fund III is focused on investing in early stage companies that develop novel therapeutics, medical devices (including digital health) or nutraceuticals, based in the Netherlands, Belgium or Germany.

The European Investment Fund (EIF), ASR as well as several Dutch and Walloon regional investment agencies are part of a strong base of LPs supporting the fund. In addition, several universities and knowledge institutions, amongst which Sanquin, Utrecht University and UMC, Radboud UMC, Brightlands Maastricht, Delft Enterprises and KU Leuven have backed the fund.

The Fund will identify early stage investment opportunities, often still at an academic project/spin-off stage, and work actively with management to develop initial preclinical proof of concept and attract follow-on investment rounds, on its way to realize meaningful healthcare impact.

Fund III will build a portfolio of 10-12 investments, comprising promising and impactful Dutch, Belgian and German early-stage ventures. The fund has made three investments to date: Alesta Therapeutics (Leiden, The Netherlands), EsoBiotec (Gosselies, Belgium) and Pan Cancer T (Rotterdam, The Netherlands).

Harrold van Barlingen, Managing Partner and founder of Thuja, said:

“We are very pleased with the closing of this new fund, which is more than double the size of our previous fund. It allows us to continue and accelerate our successful strategy of building life science companies and thus promote innovation to reach and benefit patients. We are now reinforcing our team to expand our reach and scale our successful model”.

Michel Briejer, Managing Partner of Thuja, said:

“We have expanded our network of academia and knowledge institutions within the framework of this new fund, are actively collaborating with these institutions. In this way we can access a rich source of innovation and at the same time provide support and advice to our counterparts, which is to the benefit of all involved. We are thrilled to have their vote of confidence and their contribution as an LP to the fund”.


For more information, please contact:
Harrold van Barlingen, Managing Partner, hvb@thujacapital

About Thuja

Thuja Capital Management (Thuja) is a dedicated life sciences venture capital firm with its office in Utrecht, The Netherlands. Thuja's team currently consists of 8 professionals (scaling to 10, of which 6 hold a PhD).

Thuja has been active as an early stage life sciences investor since 2008. Since then, it has operated several funds totaling in excess of EUR 125M under management. Since then, Thuja has been involved mostly as of the start, with various successful ventures, amongst which Argenx (market cap 16.5 Bn USD), Okapi Biosciences, NightBalance and MILabs. For the active portfolio we refer to our website. To date, Thuja invested in 25 life sciences companies.

Thuja is a signatory to the United Nations Principles for Responsible Investment. Besides financial objectives, Thuja selects investments that will positively affect the health and well-being of patients.

European Investment Fund

Participation of EIF in Fund III was structured through various mandates:

> InnovFin Equity, with the financial backing of the European Union under Horizon 2020 Financial Instruments and the European Fund for Strategic Investments (EFSI) set up under the Investment Plan for Europe. The purpose of EFSI is to help support financing and implementing productive investments in the European Union and to ensure increased access to financing;

> PanEuropean Guarantee Fund (EGF) implemented by the EIF with the financial support of the Participating Member States;

> As fiduciary for the benefit and risk of Invest-NL Capital N.V.

Record changed: 2021-12-23


Picture ConsulTech GmbH Berlin Grant Application and Coordination 650x80px

More documents for Thuja Capital (Group)

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]

Please visit also our web portals for the European life sciences and the worldwide mass spectrometry industry at (European life sciences) and (worldwide mass spectrometry)

Please visit also our web portals for the life sciences in German-speaking Europe (DE, AT & CH) and the worldwide mass spectrometry industry at (life sciences in German-speaking Europe) and (worldwide mass spectrometry)


Picture EBD Group Connector Personal Networking in Life Sciences 650x80

» top